Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Wu, Bin ^a   Shen, Jinfang ^a   Cheng, Huafeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cost effectiveness; Hepatitis B; Lamivudine resistance; Rescue therapy

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CHINA; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG EFFECT; ECONOMICS; EMERGENCY TREATMENT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; METHODOLOGY; PREDICTIVE VALUE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; TEACHING; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CHINA; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EMERGENCY TREATMENT; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MARKOV CHAINS; ORGANOPHOSPHONATES; PATIENT SIMULATION; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84868509427     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-385     Document Type: Article

References (45)

1. Hepatitis B virus infection. Lee WM, N Engl J Med 1997 337 24 1733 1745 10.1056/NEJM199712113372406 9392700
2. Hepatitis B virus infection-natural history and clinical consequences. Ganem D, Prince AM, N Engl J Med 2004 350 11 1118 1129 10.1056/NEJMra031087 15014185
3. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, et al. Ann Intern Med 2009 150 2 104 110 19124811
4. Benefits and risks of nucleoside analog therapy for hepatitis B. Dienstag JL, Hepatology 2009 49 5 Suppl 112 S121 19399795
5. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Wu B, Li T, Chen H, Shen J, Value Health 2010 13 5 592 600 10.1111/j.1524-4733.2010.00733.x 20561341
6. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Marcellin P, Sung J, Piratvisuth T, Liver Int 2010 30 5 657 668 10.1111/j.1478-3231.2010.02207.x 20158610
7. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW, J Gastroenterol Hepatol 2004 19 11 1276 1282 10.1111/j.1440-1746.2004.03428.x 15482535
8. Antiviral resistance and hepatitis B therapy. Ghany MG, Doo EC, Hepatology 2009 49 5 Suppl 174 S184 19399794
9. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Lee JM, Park JY, Kim Do Y, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH, Antivir Ther 2010 15 2 235 241 10.3851/IMP1510 20386079
10. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Chen EQ, Wang LC, Lei J, Xu L, Tang H, Virol J 2009 6 163 10.1186/1743-422X-6-163 19818142
11. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. Hezode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, Dhumeaux D, Pawlotsky JM, J Hepatol 2007 46 5 791 796 10.1016/j.jhep.2007.01.018 17321635
12. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO, et al. Gut 2006 55 10 1488 1495 10.1136/gut.2005.077099 16461777
13. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A, Hepatology 2000 32 1 129 134 10.1053/jhep.2000. 8626 10869300
14. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Yoo W, Kim SO, Hepatology 2006 43 6 1385 1391 10.1002/hep.21189 16729316
15. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Ryu HJ, Lee JM, Ahn SH, Kim Do Y, Lee MH, Han KH, Chon CY, Park JY, J Med Virol 2010 82 11 1835 1842 10.1002/jmv.21898 20872709
16. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, J Gastroenterol Hepatol 2010 25 8 1374 1380 10.1111/j.1440-1746. 2010.06381.x 20659226
17. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Lee JM, Kim HJ, Park JY, Lee CK, Kim Do Y, Kim JK, Lee HW, Paik YH, Lee KS, Han KH, et al. Antivir Ther 2009 14 5 705 712 19704174
18. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, et al. Hepatol Int 2010 4 1 414 422 10.1007/s12072-009-9162-x 20305760
19. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Goulis I, Dalekos GN, Expert Rev Anti Infect Ther 2008 6 6 855 859 10.1586/14787210.6.6.855 19053898
20. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, et al. Hepatology 2008 48 1 99 108 10.1002/hep.22323 18537189
21. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, et al. Gastroenterology 2006 130 7 2039 2049 10.1053/j.gastro.2006.04.007 16762627
22. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, et al. Gut 2011 60 2 247 254 10.1136/gut.2010.223206 21036792
23. Four year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Eggers B, Yu D, Cross A, Tenney DJ, J Hepatol 2007 46 781
24. Management of chronic hepatitis B. EASL Clinical Practice Guidelines, J Hepatol 2009 50 2 227 242 10.1016/j.jhep.2008.10.001 19054588
25. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Chen CJ, Yang HI, Iloeje UH, Hepatology 2009 49 5 Suppl 72 S84 19399801
26. World Health Organization, Life tables for WHO Member States 2011 http://www.who.int/whosis/database/life-tables/life-tables.cfm.
27. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Fattovich G, Bortolotti F, Donato F, J Hepatol 2008 48 2 335 352 10.1016/j.jhep.2007.11.011 18096267
28. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM, Ann Intern Med 2005 142 10 821 831 15897532
29. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, et al. J Hepatol 2008 48 6 923 931 10.1016/j.jhep.2008.02.019 18433925
30. Effectiveness of long-term combination therapy with adefovir dipivoxil and lamivudine in patients with hbeag-negative chronic hepatitis b and lamivudine resistance. Manolakopoulos S, Striki A, Papatheodoridis GV, Deutsch M, Mela M, Tzourmakliotis D, Manesis EK, Archimandritis AJ, Hepatology 2009 50 4 455
31. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG, Aliment Pharmacol Ther 2008 27 12 1240 1252 10.1111/j.1365-2036.2008.03691.x 18373637
32. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Buti M, Brosa M, Casado MA, Rueda M, Esteban R, J Hepatol 2009 51 4 640 646 10.1016/j.jhep.2009.04.013 19576651
33. Cost of chronic hepatitis B infection in China. Guan ZQ, Dong ZH, Wang QH, Cao DX, Fang YY, Liu HT, Iloeje UH, J Clin Gastroenterol 2004 38 10 175 S178 15602167
34. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH, Value Health 2008 11 3 527 538 10.1111/j.1524-4733.2007.00297.x 18179664
35. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Barton GR, Briggs AH, Fenwick EA, Value Health 2008 11 5 886 897 10.1111/j.1524-4733.2008. 00358.x 18489513
36. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B, Value Health 2004 7 5 518 528 10.1111/j.1524-4733.2004.75003.x 15367247
37. Development of WHO guidelines on generalized cost-effectiveness analysis. Murray CJ, Evans DB, Acharya A, Baltussen RM, Health Econ 2000 9 3 235 251 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O 10790702
38. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis. Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC, Med Care 2011 49 3 267 272 10.1097/MLR.0b013e31820192cd 21224742
39. EASL Clinical Practice Guidelines. Pawlotsky JM, J Hepatol 2009 50 2 243 10.1016/j.jhep.2008.11.012 19081157
40. National Institutes of Health consensus development conference statement: management of hepatitis B. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, et al. Hepatology 2009 49 5 Suppl 4 S12 19399804
41. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S, Hepatol Int 2008 2 3 263 283 10.1007/s12072-008-9080-3 19669255
42. Emerging issues in public health: a perspective on China's healthcare system. Ling RE, Liu F, Lu XQ, Wang W, Public Health 2011 125 1 9 14 10.1016/j.puhe.2010.10.009 21168175
43. The challenges of healthcare reforms in China. Li L, Public Health 2011 125 1 6 8 10.1016/j.puhe.2010.10.010 21168176
44. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M, Int J Technol Assess Health Care 2011 27 1 71 76 10.1017/S0266462310001194 21262069
45. A multinational study of health state preference values associated with chronic myelogenous leukemia. Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J, Value Health 2010 13 1 103 111 10.1111/j.1524-4733.2009.00573.x 19659707